Table 1.

Baseline characteristics of patients

	Oral fluoroquinolone step down (n = 130)	Oral beta-lactam step down (n = 77)	p-value
Age, median, years (IQR)	70.5 (56.25–80.75)	71 (54–80)	0.72
Sex			0.92
Female	92 (71)	54 (70)
Male	38 (29)	23 (30)
Comorbidities
Diabetes Mellitus	29 (22)	20 (26)	0.55
Heart Conditions	75 (58)	43 (56)	0.8
Chronic Kidney Disease	10 (8)	3 (4)	0.28
Peripheral Vascular Disease	6 (5)	4 (5)	0.85
Asthma or COPD	14 (11)	7 (9)	0.7
Liver Cirrhosis	1 (1)	2 (3)	0.56
Recurrent UTI Risk factors	38 (29)	22 (29)	0.92
IVDU	5 (4)	0 (0)	0.16
Hepatitis C	1 (1)	1 (1)	1.0
HIV	0 (0)	0 (0)	1.0
Immunocompromised	5 (4)	4 (5)	0.65
Charlson comorbidity index, median (IQR)	1 (0–2)	1 (0–3)	0.96
Catheter associated UTI	6 (5)	4 (5)	0.85
Hospital admission	101 (78)	62 (81)	0.63
ICU admission	9 (7)	5 (6)	0.91
Sepsis	31 (25)	25 (33)	0.2
Septic shock	8 (6)	5 (6)	0.92
Pitt bacteremia score, median (IQR)	0.5 (0–1)	1 (0–1)	0.53
Site of acquisition			0.02
Community-acquired	110 (85)	53 (69)
Community-acquired health-care associated	15 (12)	20 (26)
Hospital-acquired	5 (4)	4 (5)
Beta-lactam allergy	15 (12)	7 (9)	0.58
Inadequate empiric treatment	1 (1)	1 (1)	1.0
Stable at oral switch	125 (96)	74 (96)	0.99
Duration of intravenous treatment, median, days (IQR)	5 (3–7)	5 (3–7)	0.20
Duration of oral treatment, median, days (IQR)	7 (7–10)	7 (5.75–10)	0.38
Total treatment duration, median, days (IQR)	14 (12–14)	14 (11–14)	0.91

Data are number (percentage) of patients unless otherwise indicated

Abbreviations: COPD chronic obstructive pulmonary disease, ICU intensive care unit, IVDU intravenous drug use, UTI urinary tract infection;